Xenomics' Medical DNA Technology Detailed in new Edition of Textbook on Advanced Molecular Diagnostics
News Apr 20, 2006
Xenomics, Inc. has announced that a team of Company scientists has contributed a chapter about the Xenomics' proprietary Transrenal DNA technology platform in a new edition of a leading scientific textbook about key advances and topics in the field of modern molecular diagnostic advancements.
The book, entitled "Clinical Applications of PCR," is considered one of the most comprehensive publications about the DNA detection field known as polymerase chain reaction, an indispensable technique in modern molecular diagnostics.
The newly published edition of the book contains a chapter contributed by Xenomics scientists Dr. Hovsep S. Melkonyan, Dr. L. David Tomei and D. Samuil R. Umansky, who are all co-founders and current senior executives of the Company.
In the chapter, "Novel Applications of Polymerase Chain Reaction to Urinary Nucleic Acid Analysis," the Xenomics scientists describe the principals and applications of the Company's proprietary Transrenal-DNA (Tr-DNA) diagnostic platform technology.
Currently, Xenomics is developing this platform technology into a pipeline of medically needed diagnostic products to address multibillion-dollar marketplace opportunities within the healthcare industry.
"The inclusion of this chapter regarding our science and technology in a text of this prominence is an important recognition of the importance of Transrenal-DNA and Xenomics' work in the field of molecular diagnostics," said Dr. Tomei, CEO of Xenomics.
"We're honored to be part of this new edition. We believe it is clear that Transrenal-DNA technology has the potential to usher in a new era of perfectly safe, noninvasive, painless and highly accurate medical diagnostics for an extremely large number of health care applications."
"Clinical Applications of PCR" was edited by Y. M. Dennis Lo, Rossa W. K. Chiu and K. C. Allen Chan, and published this year by Humana Press.
Xenomics' clinical research programs are focused on developing commercial Tr-DNA tests for infectious diseases such as HIV/AIDS and tuberculosis, prenatal conditions, cancer diagnostics and organ transplant monitoring.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.